Abstract
Many progresses have been made in the management of non-Hodgkin's lymphoma and Hodgkin's lymphoma. Newer chemotherapeutic regimens, extended use of PET to evaluate the stage and mainly the response after treatment, rituximab and other monoclonal antibodies, radioimmunoconjugates, and allogeneic stem cell transplantation, all contribute to a better treatment of these diseases. Furthermore, risk-adapted treatment can reduce late toxicities, such as cardiovascular disease, secondary myelodysplastic syndrome, and solid tumors.
Original language | English |
---|---|
Pages (from-to) | 101-110 |
Number of pages | 10 |
Journal | Update on Cancer Therapeutics |
Volume | 2 |
Issue number | 2 |
DOIs | |
Publication status | Published - Jun 2007 |
Keywords
- Chemotherapy
- Hodgkin's lymphoma
- Non-Hodgkin's lymphoma
- PET
ASJC Scopus subject areas
- Cancer Research
- Oncology